Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.

Lipson EJ, Drake CG.

Clin Cancer Res. 2011 Nov 15;17(22):6958-62. doi: 10.1158/1078-0432.CCR-11-1595. Epub 2011 Sep 7. Review.

2.

Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically.

Ryan CJ, Tindall DJ.

J Clin Oncol. 2011 Sep 20;29(27):3651-8. doi: 10.1200/JCO.2011.35.2005. Epub 2011 Aug 22. Review.

PMID:
21859989
3.

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.

Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA.

BJU Int. 2012 Jan;109(1):32-9. doi: 10.1111/j.1464-410X.2011.10422.x. Epub 2011 Jul 20.

4.

Abiraterone and increased survival in metastatic prostate cancer.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators.

N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.

5.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R.

Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Review.

PMID:
21074069
6.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
7.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.

Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.

PMID:
20888992
8.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators.

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.

9.

Prostate cancer as a model for tumour immunotherapy.

Drake CG.

Nat Rev Immunol. 2010 Aug;10(8):580-93. doi: 10.1038/nri2817. Review.

10.

DNA vaccines for the treatment of prostate cancer.

Alam S, McNeel DG.

Expert Rev Vaccines. 2010 Jul;9(7):731-45. doi: 10.1586/erv.10.64. Review.

PMID:
20624047
11.

Improved survival with ipilimumab in patients with metastatic melanoma.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.

N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

12.

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Weiner LM, Surana R, Wang S.

Nat Rev Immunol. 2010 May;10(5):317-27. doi: 10.1038/nri2744. Review.

13.

Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.

Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH.

Cancer. 2010 Feb 15;116(4 Suppl):1075-83. doi: 10.1002/cncr.24795.

14.

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.

J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.

15.

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.

Cancer Immunol Immunother. 2010 May;59(5):663-74. doi: 10.1007/s00262-009-0782-8. Epub 2009 Nov 5.

16.

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.

McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G.

J Clin Oncol. 2009 Sep 1;27(25):4047-54. doi: 10.1200/JCO.2008.19.9968. Epub 2009 Jul 27.

17.

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.

Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F.

J Immunol Methods. 2009 Aug 31;348(1-2):9-17. doi: 10.1016/j.jim.2009.06.004. Epub 2009 Jun 22.

PMID:
19552894
18.

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL.

Expert Opin Investig Drugs. 2009 Jul;18(7):1001-11. doi: 10.1517/13543780902997928. Review.

19.

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.

Koh YT, Gray A, Higgins SA, Hubby B, Kast WM.

Prostate. 2009 May 1;69(6):571-84. doi: 10.1002/pros.20906.

20.

The anticancer immune response: indispensable for therapeutic success?

Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G.

J Clin Invest. 2008 Jun;118(6):1991-2001. doi: 10.1172/JCI35180. Review.

Items per page

Supplemental Content

Write to the Help Desk